Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine + low-dose cytarabine followed by azacitidine for elderly untreated AML
ChiCTR1900026877Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine, cytarabine and azacitidine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: complete remission. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
cladribinecytarabineazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900026877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026877.